Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin
Public ClinicalTrials.gov record NCT00484419. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Effects of Colesevelam HCl, Avandia® (Rosiglitazone Maleate), or JanuviaTM (Sitagliptin) on Glycemic Parameters and Lipid Profiles in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Monotherapy
Study identification
- NCT ID
- NCT00484419
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Daiichi Sankyo
- Industry
- Enrollment
- 169 participants
Conditions and interventions
Conditions
Interventions
- Colesevelam HCl Drug
- rosiglitazone maleate Drug
- sitagliptin phosphate Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2007
- Primary completion
- Mar 31, 2008
- Completion
- Mar 31, 2008
- Last update posted
- Oct 3, 2016
2007 – 2008
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | La Mesa | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Los Gatos | California | — | — |
| Not listed | San Antonio | California | — | — |
| Not listed | Chiefland | Florida | — | — |
| Not listed | Gary | Indiana | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Dearborn | Michigan | — | — |
| Not listed | West Bloomfield | Michigan | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Yonkers | New York | — | — |
| Not listed | Lexington | North Carolina | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Munroe Falls | Ohio | — | — |
| Not listed | Zaneville | Ohio | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Jersey Shore | Pennsylvania | — | — |
| Not listed | Clemson | South Carolina | — | — |
| Not listed | Harriman | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00484419, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 3, 2016 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00484419 live on ClinicalTrials.gov.